Latest Cns Response Inc. (CNSO) Headlines New
Post# of 5
Posted On: 03/09/2014 10:43:14 AM
Latest Cns Response Inc. (CNSO) Headlines
New Pacific Reports Financial Results for the Three and Six Months Ended December 31, 2013-Appoints President and Senior Vice-President
Marketwire Canada - Wed Feb 12, 4:05PM CST
New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX:NUX) today announced its unaudited condensed consolidated interim financial results for the three and six months ended December 31, 2013.
New Study Says Just 5% of Mental Health Patients Receive Objective Test Before Getting Prescription Drugs
GlobeNewswire - Thu Dec 19, 10:41AM CST
96% of Patients Expect Doctor to Have Objective Information
CNS Response, Inc. Presenting at the 6th Annual LD MICRO Conference in Los Angeles
GlobeNewswire - Wed Nov 27, 8:45AM CST
CNS Response, Inc. (OTCBB:CNSO) announced today it will present at the Sixth Annual LD MICRO Conference on Thursday, December 5, 2013, at 12:00 noon (PT) at the Luxe Sunset Bel Air, Los Angeles, California.
CNS Response Inc concludes USD2m in private placement
M2 - Tue Sep 17, 8:55AM CDT
Web neuroinformatic company CNS Response Inc (Other OTC:CNSO) revealed on Monday the the completion of a USD2m in a private placement of common stock.
CNS Response Completes $2 Million Financing
GlobeNewswire - Mon Sep 16, 5:39PM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced the completion of a private placement of $2 million from the sale of common stock at $.25 per share, resulting in the issuance of 8 million shares of common stock. Of the shares sold, 3,850,000 were purchased by Directors, Officers and affiliate shareholders of the Company. The remaining 4,150,000 shares were acquired by new investors and repeat investors, in each case qualified to participate in private placements pursuant to SEC rules.
Cloud Computing, E-Waste and More Hot Micro-Cap Stock Sectors
Marketwire - Mon Aug 26, 8:01AM CDT
CNS Response, Inc. (OTCQB: CNSO) provides reference data and analytic tools for clinicians and researchers in psychiatry. Treatment for mental disorders has doubled in the last 20 years and use of psychotropic medications has grown over 400% -- but treatments fail more often than they succeed and over 17 million Americans have failed two or more medication therapies for their mental disorder. Read about the company's recent debt restructuring and innovative treatment approach at this link: http://bit.ly/RESEARCHCNSO
CNS Response Announces 100% Note Conversion
GlobeNewswire - Mon Aug 19, 8:30AM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that all 25 of its note holders who have held convertible notes issued between October 2010 and February 2012 have agreed to convert $7.8 million of principal and interest into common stock. This conversion substantially reduces the Company's debt outstanding, simplifies the Company's capital structure and greatly improves the Company's working capital position.
CNS Response Announces Four New Patents
GlobeNewswire - Wed May 15, 3:30PM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that it has received four additional patents for its PEER Interactive technology. Two of the patents -- one in the US and one in Japan -- relate to the Company's method of classifying individual patients based on their unique Quantitative EEG (QEEG) responsivity profile. The third patent, issuing in Canada, relates to the Company's method of determining medication efficacy by comparing QEEG data measured before and after medication administration. The fourth patent, issuing in Japan, relates to the Company's method of recommending therapy based upon an individual's unique QEEG responsivity profile.
CNS Response Expands Its Technology to Fort Belvoir
GlobeNewswire - Fri May 10, 9:00AM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that it has opened a second site for its PEER Interactive trial at Fort Belvoir Community Hospital in Virginia, one of the Army's largest treatment facilities for active military personnel. Fort Belvoir is the second military site to participate under an approved, 2,000-soldier protocol and Cooperative Research and Development Agreement.
New Pacific Reports Financial Results for the Three and Six Months Ended December 31, 2013-Appoints President and Senior Vice-President
Marketwire Canada - Wed Feb 12, 4:05PM CST
New Pacific Metals Corp. ("New Pacific" or the "Company") (TSX:NUX) today announced its unaudited condensed consolidated interim financial results for the three and six months ended December 31, 2013.
New Study Says Just 5% of Mental Health Patients Receive Objective Test Before Getting Prescription Drugs
GlobeNewswire - Thu Dec 19, 10:41AM CST
96% of Patients Expect Doctor to Have Objective Information
CNS Response, Inc. Presenting at the 6th Annual LD MICRO Conference in Los Angeles
GlobeNewswire - Wed Nov 27, 8:45AM CST
CNS Response, Inc. (OTCBB:CNSO) announced today it will present at the Sixth Annual LD MICRO Conference on Thursday, December 5, 2013, at 12:00 noon (PT) at the Luxe Sunset Bel Air, Los Angeles, California.
CNS Response Inc concludes USD2m in private placement
M2 - Tue Sep 17, 8:55AM CDT
Web neuroinformatic company CNS Response Inc (Other OTC:CNSO) revealed on Monday the the completion of a USD2m in a private placement of common stock.
CNS Response Completes $2 Million Financing
GlobeNewswire - Mon Sep 16, 5:39PM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced the completion of a private placement of $2 million from the sale of common stock at $.25 per share, resulting in the issuance of 8 million shares of common stock. Of the shares sold, 3,850,000 were purchased by Directors, Officers and affiliate shareholders of the Company. The remaining 4,150,000 shares were acquired by new investors and repeat investors, in each case qualified to participate in private placements pursuant to SEC rules.
Cloud Computing, E-Waste and More Hot Micro-Cap Stock Sectors
Marketwire - Mon Aug 26, 8:01AM CDT
CNS Response, Inc. (OTCQB: CNSO) provides reference data and analytic tools for clinicians and researchers in psychiatry. Treatment for mental disorders has doubled in the last 20 years and use of psychotropic medications has grown over 400% -- but treatments fail more often than they succeed and over 17 million Americans have failed two or more medication therapies for their mental disorder. Read about the company's recent debt restructuring and innovative treatment approach at this link: http://bit.ly/RESEARCHCNSO
CNS Response Announces 100% Note Conversion
GlobeNewswire - Mon Aug 19, 8:30AM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that all 25 of its note holders who have held convertible notes issued between October 2010 and February 2012 have agreed to convert $7.8 million of principal and interest into common stock. This conversion substantially reduces the Company's debt outstanding, simplifies the Company's capital structure and greatly improves the Company's working capital position.
CNS Response Announces Four New Patents
GlobeNewswire - Wed May 15, 3:30PM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that it has received four additional patents for its PEER Interactive technology. Two of the patents -- one in the US and one in Japan -- relate to the Company's method of classifying individual patients based on their unique Quantitative EEG (QEEG) responsivity profile. The third patent, issuing in Canada, relates to the Company's method of determining medication efficacy by comparing QEEG data measured before and after medication administration. The fourth patent, issuing in Japan, relates to the Company's method of recommending therapy based upon an individual's unique QEEG responsivity profile.
CNS Response Expands Its Technology to Fort Belvoir
GlobeNewswire - Fri May 10, 9:00AM CDT
CNS Response, Inc. (OTCBB:CNSO) today announced that it has opened a second site for its PEER Interactive trial at Fort Belvoir Community Hospital in Virginia, one of the Army's largest treatment facilities for active military personnel. Fort Belvoir is the second military site to participate under an approved, 2,000-soldier protocol and Cooperative Research and Development Agreement.
(0)
(0)